Archived: QbD and Subjective Risk Assessments
Date: 08 January 2020
Successful risk assessment is a fundamental aspect of Quality by Design (QbD), however, risk analysis is a subjective process and is open to human bias and inaccuracy. This webinar will introduce the QbD process and the FDA’s objective with QbD, focussing on risk assessment. Different risk assessment tools were discussed and a case study, showing how a well carried out QbD risk assessment can ensure consistent quality, was presented.
Who should listen:
Chemists, engineers, analysts and formulators in pharmaceutical development. Anyone involved or interested in the risk assessment process.
This webinar was delivered by Dr Paul Murray, Paul Murray Catalysis Consulting.
If you’d like to learn more, Paul is also a tutor on the following 3-day course: